News and Trends 3 Oct 2022
Poxel granted orphan drug designation for kidney disease treatment
French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to…
Poxel
- Latest Posts
News and Trends 2 Jul 2021
Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce
As French biotech Poxel marks the first market approval of its oral type 2 diabetes medication in Japan, eyes turn…
Best in Biotech 10 Jul 2019
The Top 10 Biotechs You’ll Find in Lyon
Lyon is one of the hotspots for biotech in Europe. Here are 10 of the most successful biotech companies in…
News and Trends 9 Apr 2019
French First-in-Class Diabetes Drug Nails Phase III Trial
An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type…
ADVERTISEMENT
News and Trends 13 Mar 2018
French Biotech Takes its Oral Diabetes Drug to Phase III
Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin.…
News and Trends 12 Feb 2018
Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide
Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a…
News and Trends 9 Dec 2016
Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?
Try as we might, we can't cover all the biotech news out there. During the week, we only pick the…
News and Trends 19 Jul 2016
Poxel raises €26.5M to support Phase III trial in Diabetes
Poxel has closed a capital increase on the Euronext Paris, raising €26.5M. The money is intended to fund its plans…
News and Trends 29 May 2015
Poxel is Looking towards Japan’s Lucrative Diabetes Market
Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical…
News and Trends 3 May 2015
After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug
Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with…